Washington, D.C. 20549



Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )


Filed by the Registrant                               Filed by a Party other than the Registrant  

Check the appropriate box:



Preliminary Proxy Statement


Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))


Definitive Proxy Statement


Definitive Additional Materials


Soliciting Material Pursuant to §240.14a-12


(Name of registrant as specified in its charter)


(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check the appropriate box):







No fee required.




Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.








Title of each class of securities to which transaction applies:







Aggregate number of securities to which transaction applies:







Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):







Proposed maximum aggregate value of transaction:







Total fee paid:






Fee paid previously with preliminary materials.




Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.








Amount Previously Paid:







Form, Schedule or Registration Statement No.:







Filing Party:







Date Filed:










CONSTELLATION PHARMACEUTICALS Constellation Pharmaceuticals, Inc. Important Notice Regarding the Availability of Proxy Materials Stockholders Meeting to be held on June 02, 2021 P.O. BOX 8016, CARY, NC 27512-9903 For Stockholders of record as of April 05, 2021 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement, annual report, directions to register for the annual meeting and voting instructions go to: To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. CONTROL NUMBER For a convenient way to view proxy materials and VOTE go to Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions. To order paper materials, use one of the following methods. INTERNET TELEPHONE (866) 648-8133 * E-MAIL When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above. * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Constellation Pharmaceuticals, Inc. Meeting Type: Date: Time: Place: Annual Meeting of Stockholders Wednesday, June 02, 2021 08:00 AM, Eastern Time Annual Meeting to be held live via the Internet - please visit for more details. You must register to attend the meeting online and/or participate at SEE REVERSE FOR FULL AGENDA





Constellation Pharmaceuticals, Inc. Annual Meeting of Stockholders PROPOSALS 1. To elect three Class III directors, Scott N. Braunstein, Mark A. Goldsmith, and Jigar Raythatha, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders; 1.01 Scott N. Braunstein 1.02 Mark A. Goldsmith 1.03 Jigar Raythatha 2. To approve, on an advisory basis, the compensation paid to the Company's named executive officers. 3. To approve, on an advisory basis, the frequency of future advisory votes on executive compensation. 4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ON PROPOSALS 1, 2 AND 4 THE BOARD OF DIRECTORS RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR ON PROPOSAL 3. You may attend the Annual Meeting virtually by registering at, where you will be able to vote electronically and submit questions. In order to attend, you must register in advance at prior to the deadline of May 31, 2021 at 5:00 p.m., Eastern Time. Upon completing your registration you will receive further instructions via email, including your unique links that will allow you to access the meeting and will also permit you to submit questions.